p53 R175H mutant protein: acquired gain-of-function mechanism driving tumor metastasis via the BACH1-LSD2 ternary complex

Author: Senior Product Manager of UA Views：6

This article focuses on the gain-of-function mechanisms and pro-metastatic effects of the p53 R175H hotspot mutant protein, systematically elaborating its specific protein interaction features that distinguish it from other p53 hotspot mutant subtypes, analyzing the molecular mechanism by which it binds to the transcription factor BACH1 and recruits the histone demethylase LSD2 to form a ternary regulatory complex, thereby achieving selective regulation of BACH1's inhibitory and activating targets, and exploring the dual effects of this mechanism in antagonizing ferroptosis and promoting tumor metastasis, as well as the validation evidence from mouse genetic models.

Recent Advances
Product Information

Recent Advances

p53 R175H Mutant Protein: An Acquired-Function Mechanism Driving Tumor Metastasis via the BACH1-LSD2 Ternary Complex

Summary: This article focuses on the acquired-function mechanism and pro-metastatic role of the p53 R175H hotspot mutant protein, systematically describing its specific protein-protein interaction features that distinguish it from other p53 hotspot mutant subtypes, analyzing the molecular mechanism by which it binds to the transcription factor BACH1 and recruits the histone demethylase LSD2 to form a ternary regulatory complex, thereby achieving selective regulation of BACH1's repressive and activating targets, and discussing the dual effects of this mechanism in antagonizing ferroptosis and promoting tumor metastasis as well as the validating evidence from mouse genetic models.

I. Acquired function and pro-metastatic phenotype of p53 missense mutations.

The p53 gene is an important tumor suppressor gene, and p53 gene mutation is one of the key steps in the development of various tumors, with 40% to 50% of tumor patients carrying p53 gene mutations. Compared with simple deletion of the p53 gene, the phenotype produced by p53 missense mutations is more malignant and can lead to extensive tumor metastasis. The main reason may be that mutant p53 protein not only loses the tumor-suppressive function of wild-type p53 protein, but can also interfere with other signaling pathways through acquired-function mechanisms, thereby gaining pro-metastatic functions. Intervention targeting mutant p53 protein has long been a hotspot in the field of drug development; however, the biological regulation of different mutant p53 proteins and their specific targeted intervention have remained unclear. This knowledge gap constitutes the core scientific question of this study: do different hotspot mutant p53 proteins act through the same acquired-function mechanism, or does each possess a unique interaction network?

II. Specific binding of p53 R175H to BACH1 and its subtype selectivity.

A new research paper reveals that BACH1 and LSD2 are key proteins mediating the metastasis-promoting effect of the p53 hotspot mutant protein R175H. The study found that the p53 hotspot mutant protein p53R175H can specifically bind to the transcription factor BACH1 in vivo, thereby interfering with the biological function of BACH1, whereas other p53 hotspot mutant proteins such as p53R248W, p53R273H, and p53G245S do not bind to BACH1 nor affect its function. This discovery of subtype selectivity is of important theoretical significance——it demonstrates for the first time that the acquired-function pathways activated by mutant p53 at different sites can be entirely different, and that the mutation site not only determines the manner of conformational change of the protein but also determines the spectrum of interaction partners it can recruit.

BACH1 is a transcription factor with bidirectional regulatory functions: on the one hand, it transcriptionally represses a set of genes related to oxidative stress regulation, promoting the occurrence of ferroptosis; on the other hand, it transcriptionally activates another set of genes related to tumor metastasis, thereby promoting tumor metastasis. This property of BACH1, possessing both repressive and activating transcriptional functions simultaneously, makes it an ideal node of action for the acquired function of p53R175H——a single binding event can simultaneously alter two transcriptional programs running in opposite directions.

III. Dual effects of the p53 R175H-BACH1 axis: antagonizing ferroptosis and promoting metastasis.

The specific binding of p53R175H to BACH1, on the one hand, relieves BACH1's transcriptional repression of ferroptosis-related genes such as SLC7A11, thereby antagonizing ferroptosis and promoting tumor growth; on the other hand, it enhances BACH1's transcriptional activation of pro-metastatic molecules such as CEMIP, thereby accelerating tumor metastasis. The molecular logic of this dual effect lies in the fact that the repressive targets and activating targets of BACH1 have different regulatory requirements at the chromatin level; the binding of p53R175H alters the cofactor composition of the BACH1 complex, causing a differential shift in the regulatory direction toward the two classes of targets. The result is that tumor cells simultaneously acquire resistance to ferroptosis and enhanced migratory and invasive potential, and the superposition of these two phenotypes is precisely the functional basis for the worse prognosis of patients with p53 R175H mutations.

IV. LSD2-mediated ternary complex and the mechanism of selective target gene regulation.

The study further found that the reason the p53 hotspot mutant protein p53R175H can simultaneously regulate both the repressive and activating targets of BACH1 lies mechanistically in the fact that p53R175H can recruit a histone H3K4me1/2 demethylase, LSD2, to form a p53R175H-BACH1-LSD2 ternary regulatory complex, which achieves selective regulation of BACH1 transcriptional targets by affecting the methylation status of histones at target genes. The elucidation of this mechanism answers the key question of “how a single transcription factor is directed toward two opposite transcriptional outputs”: the demethylation of H3K4me1/2 by LSD2 alters the chromatin state of the enhancer regions of target genes, causing the transcriptional activity of the BACH1 complex to diverge at different targets. The formation of the ternary complex thus becomes the core molecular event linking mutant p53 to downstream transcriptional reprogramming.

V. Validation of the key role of BACH1 by mouse genetic models.

The team further confirmed the key role of BACH1 in mediating the pro-metastatic activity of p53R175H using mouse genetic models. p53R172H/+ knock-in mice can spontaneously develop tumors and undergo metastasis. The researchers crossed p53R172H/+ mice with BACH1 knockout mice to obtain p53R172H/+BACH1-/- mice. Compared with p53R172H/+ mice, the tumor metastasis risk of p53R172H/+BACH1-/- mice was significantly reduced and overall survival was significantly prolonged. This in vivo genetic evidence elevates BACH1 from a correlative molecule to a functionally essential factor——in the absence of BACH1, the pro-metastatic ability of p53R172H is significantly attenuated, directly demonstrating that BACH1 is an irreplaceable node in this acquired-function pathway.

VI. Conclusion.

In basic research and targeted drug development related to the p53 R175H mutant protein, high-quality recombinant p53 R175H protein is a core tool for dissecting its specific binding mechanism with BACH1, evaluating ternary complex formation, and screening targeted intervention molecules. To meet the needs of functional research on the p53 R175H mutant protein and anti-metastatic drug development, Ulab provides P53 [R175H] Protein, Human. This product is suitable for applications such as analysis of the binding activity and subtype selectivity of p53 R175H with BACH1, in vitro studies of the formation mechanism of the p53 R175H-BACH1-LSD2 ternary complex, evaluation and screening of the binding activity of small-molecule inhibitors targeting BACH1 or LSD2, and development of individualized therapeutic strategies for p53 R175H mutant tumors.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next